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Abstract
Background Refractory status epilepticus (RSE) has a
mortality of 16–39%; coma induction is advocated for its
management, but no comparative study has been per-
formed. We aimed to assess the effectiveness (RSE control,
adverse events) of the first course of propofol versus bar-
biturates in the treatment of RSE.
Methods In this randomized, single blind, multi-center
trial studying adults with RSE not due to cerebral anoxia,
medications were titrated toward EEG burst-suppression
for 36–48 h and then progressively weaned. The primary
endpoint was the proportion of patients with RSE con-
trolled after a first course of study medication; secondary
endpoints included tolerability measures.
Results The trial was terminated after 3 years, with only
24 patients recruited of the 150 needed; 14 subjects
received propofol, 9 barbiturates. The primary endpoint
was reached in 43% in the propofol versus 22% in the
barbiturates arm (P = 0.40). Mortality (43 vs. 34%;
P = 1.00) and return to baseline clinical conditions at
3 months (36 vs. 44%; P = 1.00) were similar. While
infections and arterial hypotension did not differ between
groups, barbiturate use was associated with a significantly
longer mechanical ventilation (P = 0.03). A non-fatal
propofol infusion syndrome was detected in one patient,
while one subject died of bowel ischemia after barbiturates.
Discussion Although undersampled, this trial shows sig-
nificantly longer mechanical ventilation with barbiturates
and the occurrence of severe treatment-related complica-
tions in both arms. We describe practical issues necessary
for the success of future studies needed to improve the
current unsatisfactory state of evidence.
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Introduction
Status epilepticus (SE) resistant to one-first-line (benzodi-
azepines, BDZ) and one-second-line (phenytoin, phenobar-
bital, or valproic acid) antiepileptic drug (AED) is labeled
as refractory status epilepticus (RSE) [1]. It develops in
23–44% of SE patients and has a mortality of 16–39%
[1–4]. Since SE tends to become more resistant to con-
ventional treatment with time and the number of AED used
[5], coma induction with barbiturates, propofol (PRO), or
midazolam is advocated after failure of second-line treat-
ments [6, 7].
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Most of the existing studies on RSE deal with case series
of patients receiving a single coma-inducing AED. A meta-
analysis did not disclose any significant difference of short-
term mortality among barbiturates (such as thiopental
(THP) in use in Europe, or its metabolite pentobarbital
(PTB) in North America), PRO, and midazolam; however,
treatment allocation was not randomized, patients receiv-
ing barbiturates tended to be treated more often under EEG
monitoring and experienced more often significant arterial
hypotension, and an unclear number of anoxic subjects
were included [8]. Furthermore, a single-center retrospec-
tive survey of RSE treatment taking into account several
strategies (drugs combinations, monotherapy) did not show
any outcome difference [4]. Despite the clinical impact of
RSE and the call of several authorities for a controlled
comparative study [9–11], no attempt has been undertaken
so far, possibly also due to the lack of a consensus
regarding the optimal therapeutic protocol [12, 13].
This prospective study was undertaken to assess the
effectiveness (SE control, adverse events) of a first course
of PRO versus barbiturates, the two most commonly used
agents according to the aforementioned surveys.
Methods
This was a pragmatic, randomized, single blind, multi-
center clinical trial (see Appendix) comparing PRO with
barbiturates for RSE treatment. Markedly different physi-
cal appearance, pharmacokinetics, and side effects profiles
of the drugs represent major difficulties for a double blind
study. THP was used in Switzerland, and PTB in the USA;
the pharmacological equivalence of THP and PTB was
independently confirmed for the aim of this study (E. Pe-
rucca, Pavia, Italy, personal communication, August 2005).
The study was approved by the IRB of each participating
institution.
Patients
We included adults (older than 16 years) with RSE not due to
cerebral anoxia, defined as ongoing clinical or electro-
graphical seizures, or repetitive seizures without return to the
baseline for at least 30 min despite administration of at least
one-first-line (benzodiazepine), and one-second-line AED
(mostly phenytoin, valproate, phenobarbital, and leveti-
racetam) in adequate doses, who were clinically determined
to require coma induction. Patients with known pregnancy,
known intolerance to the study drugs, mitochondrial disor-
ders, egg allergy, hypertriglycerydemia (>5 mmol/l), or
significant rhabdomyolysis (CK > 1500 U/l) on admission
were excluded.
Baseline assessment included demographics, a simpli-
fied functional score before the SE (0 = completely
independent; 1 = partially dependent; 2 = completely
dependent), history of previous seizures, concurrent med-
ications, time to first SE treatment administration, seizure
type (simple partial, complex-partial, generalized convul-
sive, nonconvulsive status in coma), consciousness before
first SE treatment, blood tests (creatinine, ASAT, ALAT,
cGT, triglycerides, CK, CRP), serum AED levels, and an
urine pregnancy test in women aged 18–50. The STESS
(status epilepticus severity score, [14]) was calculated
subsequently using age, previous seizure history, con-
sciousness, and seizure type.
Intervention
After written consent was obtained by proxy, randomiza-
tion (PRO: barbiturates; 1:1) was stratified by institution,
using blocks with sealed envelopes. Study drugs were
administered as follows. PTB (USA): bolus of 5 mg/kg IV,
then titration toward burst-suppression or, if no EEG
available, toward 2 mg/kg/h until EEG was available. THP
(Switzerland): bolus of 2 mg/kg IV, then titration toward
burst-suppression or, if no EEG available, toward 4 mg/kg/
h until EEG was available. PRO (USA and Switzerland):
bolus of 2 mg/kg, then titration toward burst-suppression
or, if no EEG available, toward 5 mg/kg/h until EEG was
available. In each arm, a BDZ was administered at low
dose (lorazepam: 4 mg/24 h, or clonazepam 2 mg/24 h)
throughout the study period, to reduce required doses of
study drugs [15]. The second-line AED(s) were adminis-
tered in usual daily doses. Interruption criteria were a PRO
infusion syndrome (PRIS) with any of the following:
CK > 2000 U/l, triglycerides > 5.3 mmol/l (=500 mg/
dl), or progressive lactic acidosis >6 h after treatment
initiation (>2.5 mmol/l with bicarbonate <20 mmol/l)
[16], not due to sepsis, and after lactate normalization.
Furthermore, treatment-refractory arterial hypotension (as
judged necessary to reverse by the attending physician) and
hypersensitivity reaction with rash, fever, and lymphade-
nopathy also represented interruption criteria, implying
discontinuation of the study drug.
EEG monitoring had to be started at least within 12 h
of the beginning of the intervention. Burst-suppression
(5–15 s interburst intervals) was continued for 36–48 h
under EEG control, after which the study drug was pro-
gressively weaned over at least 24 h. The treating clinician,
if considering that RSE remained insufficiently controlled,
according to the pragmatic intent of the study was allowed
to pursue the best treatment (retry the study drug, or switch
it, or combine it with another compound). The controlled
application of the study drug ended after the first weaning
attempt.
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Daily assessment (during the controlled study drug
application, and until 48 h after evaluation of treatment
success) included clinical and EEG seizure activity, central
body temperature, determination of triglycerides, CK,
CRP, glucose, blood gas analysis, lactate (at least twice a
day), blood levels and dosage of other administered AED,
episodes of oxygen desaturation <90%, episodes of arte-
rial hypotension (systolic BP <90 mmHg refractory to
volume expansion and requiring vasopressors), cardiac
arrhythmia (sustained supraventricular or ventricular tachy-
cardia, bradycardia <50 bpm, new heart conduction blocks)
associated with hemodynamic instability and requiring
treatment, infections requiring antibiotic treatment, dopp-
ler/duplex confirmed deep vein thrombosis, scintigraphy or
CT confirmed pulmonary embolism, and administered dose
of the study drug.
Long-term assessment (3 weeks and 3 months) was
performed using hospital charts and semi-structured phone
interviews, and included SE etiology (classified according
to [17]) and the simplified functional score (0–3, as above;
3 = death).
Statistical Analysis
The primary objective was to compare the proportion of
patients with successful RSE control after 36–48 h of a
stable burst-suppression pattern, defined by all the fol-
lowing criteria: patient alive; no clinical need to re-titrate
the study drug to a higher dose during the first 7 days after
initial weaning of the study drug; and B1 discrete seizure
(defined electrographically as evolving focal or generalized
pattern for more than 5 s and less than 2 min) per hour
during the 2 h after which the EEG became continuous (a
single seizure lasting more than 2 min was sufficient for a
treatment failure). In case of PLEDs (periodic lateralized
epileptiform discharges), the average interdischarge inter-
val had to be >1 s. Persistent interictal epileptiform EEG
activity was not counted as treatment failure. A total of 150
patients, 75 in each treatment arm, would be needed to
detect an absolute difference of 22% (relative differ-
ence = 30%) of the primary outcome toward the worse
treatment, with a = 0.05 (two-sided) and b = 0.2. It was
assumed that 13 centers recruiting each 4–5 patients per
year over 3 years would be needed.
Secondary outcome measures were: the functional
clinical outcome at day 21, and at 3 months according to
the functional score, length of ventilator treatment in
survivors, incidence of thromboembolism, incidence of
infectious complications, incidence of hypotension requir-
ing specific treatment, and incidence of PRIS or other
severe complications.
Calculations were performed using the release 9 of the
Stata software (College Station, TX), applying 2-sided
Fisher exact tests for comparisons of categorical data, and
Mann–Whitney U tests for continuous data. All the out-
comes were analyzed per intention to treat in patients
having received at least one dose of the study drug.
Results
Between November 2006 and December 2009, 24 patients
were randomized in five centers (see Appendix, Fig. 1),
while five other centers did not recruit any subject and
Analysed (n= 14) 
♦ Excluded from analysis (n=0)
Lost to follow-up (n=0) 
Discontinued intervention (propofol infusion 
syndrome (1), unable to reach burst-
suppression (2)) (n=3) 
Allocated to propofol (n=14) 
♦ Received allocated intervention (n=14)
♦ Did not receive allocated intervention (n=0)
Lost to follow-up (n=0) 
Discontinued intervention (unable to maintain 
burst-suppression due to hypotension) (n=3)
Allocated to intervention (n=10) 
♦ Received allocated intervention (n=9)
♦ Did not receive allocated intervention 
(awoke) (n=1)
Analysed (n= 9) 
♦ Excluded from analysis (n=0)
Randomized (n=24) Fig. 1 Flow diagram of the
study
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three withdrew their participation. At the leading recruiting
center (CHUV Lausanne), only 10/18 (55%) of the eligible
patients were recruited (mainly because the on-call neu-
rologist did not activate the protocol); this proportion may
be even lower in other hospitals. Owing to this insufficient
recruitment, the study was terminated.
One patient did not receive the allocated treatment
(THP) because he started to awaken shortly after ran-
domization. We present here the results of 23 patients who
received at least one study drug dose. Table 1 summarizes
baseline characteristics, including SE episode severity,
which did not differ significantly among the groups. Eti-
ologies were very variable: in the PRO versus barbiturate
groups, there were 3 versus 1 cryptogenic causes, 2 versus
2 acute infections, 3 versus 0 acute strokes, 1 versus 2 AED
withdrawals, 1 versus 0 de novo CJD, and 0 versus 1
autoimmune encephalitis, 0 versus 1 severe metabolic
disturbances, 2 versus 2 ancient strokes or brain traumas,
and 2 versus 1 brain tumors.
As seen in Fig. 1, in the PRO, arm treatment was
interrupted prematurely in three patients: one had a PRIS
(see below); the others could not reach a satisfactory burst-
suppression pattern under infusions speed in agreement
with hospital’s guidelines (discouraging in the US partici-
pating Centers PRO administration at rates higher than
5 mg/kg/h). Interruptions occurred also on the barbiturates
arm (three subjects), all following treatment-refractory
hypotension preventing adequate dosage to reach a burst-
suppression pattern. The outcome measures are illustrated
in Table 2; the primary outcome was reached in 43%
patients treated with PRO and 22% with barbiturates, and
the majority of the patients who failed the first RSE
treatment course were subsequently controlled. Functional
outcome at 3 weeks and 3 months, as well as in-hospital
mortality, was comparable among the treatment arms.
Regarding side effects, there was no meaningful dif-
ference among the groups regarding thromboembolic,
infectious, or hypotensive complications. In one patient,
PRO was interrupted within the first 24 h because of a
beginning PRIS (lactate rise from 1.1 to 2.5 mm/l, bray-
cardia to 28 bpm; PRO infusion rate 5.5 mg/kg/h at that
time). She was treated with midazolam and left the hospital
alive (but did not return to baseline at 3 months, likely due
to the underlying encephalitis). In another subject who
Table 1 Baseline patients’ characteristics according to administered
treatment
Propofol BBT P Test
Patients 14 9
Female gender 7 (50%) 6 (66%) 0.67 Fisher
Age (years, median, range) 57 (26–87) 64 (16–78) 0.95 U
Acute symptomatic RSE 8 (57%) 7 (77%) 0.34 Fisher
Previous epilepsy 6 (43%) 6 (66%) 0.40 Fisher
Simple- or Complex-
partial SE
5 (36%) 5 (55%) 0.42 Fisher
STESS C 3 8 (57%) 3 (33%) 0.40 Fisher
SE treatment initiated > 1 h 9 (64%) 7 (77%) 0.66 Fisher
BBT barbiturates; RSE refractory status epilepticus; SE status epi-
lepticus; STESS status epilepticus severity score, where C 3 is
considered severe [14]
Table 2 Outcome data
Propofol BBT P Test
Patients 14 9
Efficacy
RSE controlled with first course of study drug 6 (43%) 2 (22%) 0.40 Fisher
RSE treated subsequently 4/8 (50%) 5/7 (71%) 1.00 Fisher
Functional outcome at 3 weeks (returned to baseline) 5 (36%) 3 (33%) 1.00 Fisher
Functional outcome at 3 months (returned to baseline) 5 (36%) 4 (44%) 1.00 Fisher
Mortality 6 (43%) 3 (33%) 1.00 Fisher
Tolerability
Thrombotic/embolic complication 0 0 1.00 Fisher
Infections requiring antibiotics 7 (50%) 6 (66%) 0.67 Fisher
Hypotension requiring specific treatment 7 (50%) 5 (55%) 1.00 Fisher
Other severe complications 1 (7%)a 1 (11%)b 1.00 Fisher
Study drug administration (days, median, range) 2.5 (0–7) 2 (0–4) 0.45 U
Intubation time in survivors (days, median, range) 4 (2–28) 13.5 (8–70) 0.03 U
BBT barbiturates; RSE refractory status epilepticus
a Propofol infusion syndrome (PRIS), not fatal
b Ileus with diffuse intestinal ischemia, fatal
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received THP, massive intestinal ischemia developed
shortly after THP weaning (EEG still suppressed), and the
patient died; he has been previously described in detail
[18].
Maximal PRO infusion rates were similar in Switzerland
(nine patients; median 5.5 mg/kg/h, range 2–10.9) and the
US (five patients; median 5 mg/kg/h, range 2–7.1). In
the barbiturates arm, THP was used in seven patients (in
Switzerland; median 7 mg/kg/h, range 4–20) and PTB in
two subjects (in the US; 2 and 3 mg/kg/h). Excluding
subjects in whom the study agent was interrupted, a burst-
suppression pattern was achieved under a median of 5 mg/
kg/h (range 2–10.9) for PRO and 6.7 mg/kg/h (range 4–20)
for THP. Dose weanings occurred over 48 h in all patients
apart from two subjects on PRO (96 h). Despite the fact
that PRO was administered somewhat longer than barbi-
turates, the only statistically significant difference was
related to the longer mechanical ventilation in patients
treated with barbiturates. During RSE treatment, several
AEDs were prescribed concomitantly, without differences
among the groups (phenytoin, levetiracetam, topiramate,
and valproate more often than lamotrigine, phenobarbital,
and pregabalin).
Conclusion
This trial had to be prematurely stopped because of
insufficient recruitment; however, to the best of our
knowledge it represents the first attempt to prospectively
compare PRO and barbiturates for RSE treatment, and
carries three important messages. First, while RSE control
seemed somewhat more frequent (albeit not significantly)
after PRO, medium-term functional outcome and mortality
appear similar in the two groups. Second, it demonstrates
in a randomized trial that the duration of mechanical
ventilation was significantly longer in patients treated with
barbiturates. Third, such a study was difficult to carry out
because of several major issues that need to be addressed in
any future attempts.
This study did not disclose any significant difference
between PRO and barbiturates in terms of RSE control,
mortality, or functional outcome. Premature interruption of
study drug administration was similar in both groups, but
reasons differed (hypotension for barbiturates; PRIS and
incomplete EEG suppression for PRO). Previous non-ran-
domized analyses came to similar conclusions [4, 8]; while
an older non-randomized study found a non-significant
better RSE control and a lower mortality with PTB than
PRO [19]. The primary outcome showed actually an
absolute difference of 21%, and a relative difference of
95%; 43% of patients after PRO versus 22% after barbi-
turates were permanently controlled after a first course of
burst-suppression. While this was not statistically signifi-
cant because of the modest sample size, and the results
must be viewed in the context of lack of double blinding,
we believe that these data need to be addressed in future
studies. It is also concerning that, overall, only 35% (8/23)
RSE patients were treated with either agent after the first
course; the fact that by the end of their hospitalization the
majority of early non-responders (9/15, 60%) were subse-
quently controlled (rising the overall treatment rate to
17/23, 73%) may suggest that the first burst-suppression
course was too short for several patients, that currently
used third line SE treatments are suboptimal, or that a
longer time is needed to get the underlying etiology under
control. Further studies need to address this important
issue.
The only significant difference between treatment
groups was the longer duration of mechanical ventilation in
subjects allocated to barbiturates, though without correc-
tion for multiple comparisons owing to the small sample
size. PRO has a short half-life of about 140 min after
prolonged perfusion [20], allowing a rapid titration and
withdrawal. Conversely, after prolonged administration,
barbiturates have a much longer elimination half-life than
PRO (THP 14–36 h; PTB 15–22 h) [21, 22]. While the
need of longer mechanical ventilation with barbiturates
was not found in an earlier report analyzing PRO and PTB
[19] and was not described in the Claassen’s meta-analysis
[8], it was suggested by the works of Parviainen et al. [23,
24], although these did not involve a randomized popula-
tion. A significantly longer hospitalization after barbitu-
rates as compared to PRO or midazolam was also
previously described [4]. This point, implying higher costs
and a greater risk of in-hospital complications, represents
an important drawback for the use of barbiturates, since
there is no current evidence that their efficacy on RSE
might be better than with other anesthetics.
Regarding other side effects, arterial hypotension,
thrombo-embolic disorders, and infections were compara-
ble in the two arms, thus not supporting assumptions that
barbiturates lead to more profound cardiovascular depres-
sion [8] or infections [25]. While those conditions may be
treated relatively easily, our study confirms that coma
induction in the setting of RSE may be associated with
potentially fatal complications, such as gastrointestinal
paralysis and PRIS. This complication was detected early
and thus did not result in a fatality, underscoring the need
for a serial biological monitoring in this setting (particu-
larly lactate, CK and triglycerides). As compared to a
recent retrospective survey reporting PRIS in 14/31 (45%)
patients receiving PRO, of whom two were fatal [26], the
incidence in our prospective study is considerably lower
(7%). While this may be related to a selection bias, the
concomitant use of BDZ in our study may have lowered
8 Neurocrit Care (2011) 14:4–10
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this proportion. In any case, this trial confirms that RSE
treatment may lead to potentially fatal complications, and
should therefore carefully evaluated in those RSE groups
that are felt to represent less dangerous forms (such as
complex-partial RSE) [1, 7, 10].
Finally, this trial could not be completed because of an
insufficient recruitment, as after 3 years only 1/6 of the
target sample size was included. Several reasons accounted
for this. The most important is probably related to the
recruitment in this clinical setting, characterized by a ‘‘low
frequency’’ of eligible patients (about 4–8 per year in each
Center), implying a continuous and thorough information
of all participants managing RSE (emergency specialists,
neurologists, intensivists) about the study. Even with con-
sequent training, the center with most included patients
‘‘missed’’ 45% of subjects, nearly all admitted overnight or
on weekends. Moreover, the US sites could not be finan-
cially supported, as several institutions and pharmacological
companies declined our applications. It is likely that lack of
funding further complicated the practical management of the
study in those centers, which ultimately did not join, or did
not recruit any patient.
This pragmatic study confirms that RSE is a serious
condition with important morbidity and mortality. Treat-
ment of SE, and particularly RSE, mostly relies on expert
opinions and data of low evidence level since several
decades [6]. While it appears mandatory to improve the
current situation, a future study will need to be performed
by at least 25–30 centers over several years, with a dedi-
cated central management and adequate funding. In view
of the tolerability issues related to barbiturates and PRO,
inclusion of a third treatment arm (midazolam) seems
advisable, even if this will increase the required sample
size.
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